Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 study 会议名称：Clinical Trials Plenary 1: New Frontiers in Precision Oncology 时间：2026年4月19日（周日）13:00–15:00 报告编号：CT020 该研究将以口头报告形式在临床试验全体大会上展示。
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study 会议名称：Advances in Precision Oncology 时间：2026年4月21日（周二）14:30–16:30 报告编号：CT303 该研究将以口头报告形式在临床试验专题研讨会上展示。
海报展示详情如下：
First in human phase 1 study of D3S-002, a purposely designed ERK1/2 inhibitor, in advanced solid tumors with MAPK pathway mutations 会议名称：First-in-Human Phase I Clinical Trials 时间：2026年4月20日（周一）9:00–12:00 展区：Poster Section 50 展板编号：20 摘要编号：CT060
First-in-human clinical pharmacokinetic prediction of D3S-003, an orally bioavailable dual-state KRAS G12D inhibitor 会议类别：Experimental and Molecular Therapeutics 会议名称：Quantitative Pharmacology and Translational Modeling 时间：2026年4月20日（周一）9:00–12:00 展区：Poster Section 17 展板编号：19 摘要编号：1831
D3S-003, an orally bioavailable potent and selective dual-state inhibitor targeting both GDP- and GTP-bound KRAS G12D 会议类别：Experimental and Molecular Therapeutics 会议名称：Novel Antitumor Agents 2 时间：2026年4月21日（周二）9:00–12:00 展区：Poster Section 17 展板编号：12 摘要编号：4569
